Su Gülsün BERRAK, Ahmet SOYSAL, Emine TÜRKKAN, Cengiz CANPOLAT

GEMCITABINE-ASSOCIATED REVERSIBLE ENCEPHALOPATHY A CASE REPORT

ISSN: 1019-1941
Yayın Aralığı: Yılda 3 Sayı
Başlangıç: 1988
Yayıncı: Marmara Üniversitesi

patient with metastatic Ewing's sarcoma who developed encephalopathy after treatment with gemcitabine, and his rapid recovery after discontinuation of the drug.Key Words: Gemcitabine, Neurotoxicity, Pediatric cancer

___

Pavlakis N, Bell DH, Millward MJ, et al. Ratal pulmonary toxicity resulting from treatment with gemcitabine. Cancer 1997; 80: 286-291.
Green MR. Gemcitabine safety overview. Semin Oncol 1996; 23: S32-S35.
Gemzar product labeling. Indianapolis, IN, Eli Lilly and Company, March 1997.
Hinchey J, Chaves C, Appignani B, et al. /I reversible posterior leukoencephalopathy syndrome. N Eng! J Med 1996; 334: 494-500.
Ay H, Buonannao F, Schaefer F, et al. Posterior leukoencephalopathy without severe hypertension. Utility of diffusion- weighted MRI. Neurology 1998; 51: 1369- 1376.
Vaughn D, Jarvik J, Hackney D, el al. High- dose cytarabine neurotoxicity. MR findings during the acute phase. Am J Neuroradiol 1993; 14: 1014-1016.
Rontos HA, Wei EP, Deitrich D. Mechanism of cerebral arteriolar abnormalities after acute hypertension. Am J Physiol 1981; 240: 511- 527.
Oelanty N, Vaughan C, Frucht S, Stubgen P.
Erythropoe tin-associated hypertensive
posterior leukoencephalopathy. Neurology 1997; 49: 686-689.
lilion AD, Kallesen J, Cow! CT, et al. Ceftazidime-related nonconvulsive status epilepticus. Arch Intern Med 1994; 154: 586- 589.
Herishanu YO, Zlotnik M, Mostoslavsky M, et al. Cufuroxime-induced encephalopathy. Neurology 1998; 50: 1873-1875.
Jallon P, Fankhauser L, Du Pasquier R, Coeytaux A. Severe but reversible encephalopathy associated with cefepime. Neurophysiol Clin 2000; 30: 383-386.